Company news
Chengdu Olymvax Biopharmaceuticals Inc. Class A (SSE:688319) news
Chengdu Olymvax Biopharmaceuticals Inc. Class A news releases on 6ix. Latest, Sep 1, 2026: "Chengdu Olymvax Biopharmaceuticals Inc."Announcement…
Press releases & updates
"Chengdu Olymvax Biopharmaceuticals Inc."Announcement on Shareholding Reduction Plan of a Director and Senior Management Member
August 31, 2026
Niutech Signs Agreement with Global Energy Major for Waste Plastic Pyrolysis Line to Produce SAF
August 29, 2026
"Chengdu Olymvax Biopharmaceuticals Inc."Semi-annual Report for 2026
August 17, 2026
"Chengdu Olymvax Biopharmaceuticals Inc."Announcement on Convening the 2026 Semi-annual Performance Briefing
August 10, 2026
"Chengdu Olymvax Biopharmaceuticals Inc."Announcement on Pledge of Certain Shares Held by Shareholders Holding More Than 5% of the Shares
August 7, 2026
"Chengdu Olymvax Biopharmaceuticals Inc."Announcement on Release of Pledge of Certain Shares Held by Shareholders Holding More Than 5% of the Shares
August 4, 2026
"Chengdu Olymvax Biopharmaceuticals Inc."Voluntary Disclosure Announcement on the Unblinding Results of the Phase III Clinical Trial of Recombinant Staphylococcus Aureus Vaccine (E. coli)
July 10, 2026
"Chengdu Olymvax Biopharmaceuticals Inc."Announcement on Voluntary Disclosure of Winning the Second Prize of the 2025 National Technological Invention Award
July 8, 2026
"Chengdu Olymvax Biopharmaceuticals Inc."Announcement on Receiving Government Subsidies
June 30, 2026
Announcement on the Implementation of Repurchase and Cancellation of the Class A Restricted Shares Initially Granted under the 2023 Restricted Stock Incentive Plan
June 22, 2026
Announcement on Tax Payment Remediation
June 21, 2026
Announcement on Pledge of Some Shares Held by Shareholder with Over 5% Shares
June 11, 2026
Announcement on Release of Pledge of Partial Shares Held by Shareholders with Over 5% Shares
June 8, 2026
Announcement on Expiration of Shareholding Reduction Period and Result of No Share Reduction by Shareholders with over 5% Shares
May 25, 2026
Report for Q1 2026
April 29, 2026
Announcement on Resolutions of the 2025 Annual General Meeting
April 20, 2026
Announcement on Requesting the General Meeting to Authorize the Board of Directors to Handle Matters Related to Issuance of Shares to Specific Objects through Summary Procedure
March 30, 2026
Preliminary Earnings Estimate for 2025
February 27, 2026
Announcement on Shareholding Reduction Plan for Shareholders
January 27, 2026
Announcement on Voluntary Disclosure of Obtaining the GMP Compliance Certificate from the Philippines
January 26, 2026
Announcement on Signing a Supplementary Agreement to the Market Promotion Service Agreement for Group A and Group C Meningococcal Polysaccharide Vaccine
December 31, 2025
Announcement on Litigation Involved
December 30, 2025
Announcement on Completion of Shareholding Reduction Plan for Senior Management Members and Results of Shareholding Reduction
December 5, 2025
Announcement on Tax Payment
December 4, 2025
Announcement on Convening the Q3 2025 Performance Briefing
November 21, 2025
Announcement on the Repurchase and Cancellation of the First Batch of Class A Restricted Shares Granted under the 2023 Restricted Stock Incentive Plan, Capital Reduction, and Notification to Creditors
November 14, 2025
Announcement on Equity Change of Shareholders with Over 5% Shares Reaching 1% Scale and Results of Shareholding Reduction
October 31, 2025
Announcement on Voluntary Disclosure of Initiating Phase III Clinical Trial of the Quadrivalent Influenza Virus Split Vaccine (MDCK Cells) and Enrolling the First Subject
October 30, 2025
Announcement on Repurchase and Cancellation of the First Category Restricted Shares Initially Granted under the 2023 Restricted Stock Incentive Plan That Have Been Granted But Not Yet Released from Sales Restrictions
October 29, 2025
Announcement on Progress in the Acquisition of Minority Shareholders' Stock Rights of a Holding Subsidiary
October 17, 2025
Indicative Announcement on Change in Equity of Shareholders with Over 5% Shares Reaching 1% Scale
September 30, 2025
Indicative Announcement on Planning to Issue H-shares and Listing on the Stock Exchange of Hong Kong Limited
September 23, 2025
Announcement on Obtaining Government Subsidies
September 19, 2025
Announcement on Attending Collective Performance Briefing for Innovative Drug Industry on Semi-annual SSE STAR Market 2025
September 8, 2025
Announcement on Shareholding Reduction Plan for Senior Management Members
September 4, 2025
Announcement on Resolutions of the 4th Meeting of the 7th Board of Directors
August 31, 2025
2025 Semi-annual Report
August 28, 2025
Announcement on Abnormal Fluctuations in Stock Trading
August 20, 2025
Indicative Announcement on Disclosure for Issuing RMB Common Shares (A-shares) to Specific Targets through Simplified Procedures (2nd Revised Draft)
August 18, 2025
Announcement on Adjustment of Key Technical Personnel
July 30, 2025
Announcement on Resolutions of the 14th Meeting of the 6th Board of Supervisors
July 14, 2025
Announcement on Dilution of Immediate Return by Issuing A Shares to Specific Objects with Summary Procedures, Remedial Measures and Commitments of Relevant Entities (Revised Edition)
June 25, 2025
Announcement on Release of Pledge of Some Shares Held by Shareholders with Over 5% Shares
May 26, 2025
Indicative Announcement on Postponing Term Change of Board of Directors and Board of Supervisors and Expiration of Term of Independent Director
May 16, 2025
Announcement on Attending the Annual Collective Performance Briefing for Innovative Drug Companies on SSE STAR Market 2024 and the Q1 2025 Performance Briefing
April 25, 2025
Announcement on Resolutions of 2024 Annual General Meeting
April 18, 2025
Announcement on Convening 2024 Annual Performance and Cash Dividend Briefing
March 31, 2025
Announcement on Provision for Asset Impairment in 2024
March 28, 2025
Announcement on Change of Sponsor Institution and Sponsor Representative
March 24, 2025
Announcement on Preliminary Earnings Estimate for 2024
February 27, 2025